Expands collaboration with Altreos

RNS Number : 9585O

Cambridge Cognition Holdings PLC

13 August 2014

 



Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Expands collaboration with Altreos

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in drug development, announces the expanded scientific partnership with Altreos following the release of two draft FDA guidelines on human abuse liability ('HAL') assessments on drugs* and abuse-deterrent products.

There has been an increased demand for ways of assessing the human abuse potential of new chemical entities (NCE's). In response to this demand, Cambridge Cognition has formed a scientific partnership with Altreos Research Partners, Inc., a leading provider of scientific, regulatory and operational input on abuse liability assessments for NCE's and abuse deterrent formulations. This partnership exists to develop and supply scientific software that will identify the potential for cognitive impairment caused by NCE's and identify new abuse-deterrent products.

Altreos offers a breadth of expertise and research experience having been involved in the design and evaluation of over one hundred Phase 1 studies, including more than 50 abuse liability studies, as well as first-in-man, pharmacokinetic, drug/alcohol interaction and proof of concept studies. At the core of the abuse liability studies, cognitive assessment is undertaken with the newly launched "cloud" abuse liability product, CTIS-AL from the Company.

Scott Goss, Chief Commercial Officer at Cambridge Cognition stated: "This is an exciting development in a relationship that has grown significantly in the last year. The aim of the partnership is to maximize the combined benefits of Altreos' knowledge and experience with Cambridge Cognition's industry leading solutions for delivering computerised abuse liability tests to pharmaceutical companies assessing the abuse potential of their product.

"The Altreos team has already contributed their knowledge and expertise to the development of Cambridge Cognition's newly launched "cloud" abuse liability product, CTIS-AL. As part of the partnership, Altreos will continue to support Cambridge Cognition in ensuring that CTIS-AL remains the market leading solution for performing computerised abuse liability studies globally. In addition, Cambridge Cognition clients will now have access to Altreos' broad range of consulting services to support them in the planning of their abuse liability studies."

Dr. Megan Shram of Altreos Research Partners, added: "We are pleased to be working with Cambridge Cognition to support sponsors developing CNS products and abuse-deterrent formulations. Given the importance of the human abuse liability study in the interpretation of overall abuse potential (or deterrence), we need to be confident that study results are reliable and accurate. With an appropriately designed study and a platform such as CTIS-AL, we can be increasingly assured that the data are of high quality and can be meaningfully interpreted."

No financial details of this commercial agreement have been released at this stage.

* Drugs with abuse potential include compounds that either affect the Central Nervous System (CNS), are chemically or pharmacologically similar to other drugs with known abuse potential or exhibit psychoactive effects such as sedation, euphoria or mood change.

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Matthew Robinson/Henrik Persson/Simon Hicks	(Corporate Finance)
Elizabeth Johnson	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

Notes to editors:

Altreos Research Partners offer a breadth of expertise and research experience, and have been involved in the design and evaluation of over one hundred Phase 1 studies, including more than 50 abuse liability studies. Their expertise in abuse liability has led to invitations to present at meetings with FDA involvement, which have helped shape the regulatory landscape in this evolving area of research.

www.altreos.com 

[e-mail] 

 

END

 

 

NRASFAFIEFLSEIA